A Study of LY2484595 in Japanese Subjects

Summary

The purpose of this study is to determine if 12 weeks of treatment with LY2484595 administered as a monotherapy will significantly increase high-density lipoprotein cholesterol (HDL-C) and decrease low-density lipoprotein cholesterol (LDL-C) in Japanese participants.

Timeline

Start

2011-06

Primary completion

2012-03

Completion

2012-03

Outcome

Met primary endpoint

registry analysis (superiority or other test); 100 mg LY2484595 vs Placebo; p <0.001; LS Mean Difference 115.36 (90% CI 94.58 to 136.14); Mixed Models Analysis NCT01375075 ↗

registry analysis (superiority or other test); 100 mg LY2484595 vs Placebo; p <0.001; LS Mean Difference -23.37 (90% CI -31.37 to -15.38); Mixed Models Analysis NCT01375075 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Atorvastatin	Small molecule	10 mg	Oral
Subject	Evacetrapib	Small molecule	30 mg	Oral
Subject	Evacetrapib	Small molecule	100 mg	Oral
Subject	Evacetrapib	Small molecule	500 mg	Oral

Indications